The raised guidance signals improving operational momentum and visibility. Watch for continued execution in U.S. spine and biologics recovery; the Medicare reimbursement restoration for bone growth stimulators is a tailwind for H2. Monitor free cash flow trajectory toward breakeven and further margin expansion in upcoming quarters.
Price Chart
Executive Summary
Orthofix reported Q2 2026 revenue of $210.9M (+5% pro forma constant currency YoY) and GAAP EPS of -$0.39, beating the -$0.46 consensus. The company raised full-year 2026 guidance for net sales to $845-$855M (up $7M) and adjusted EBITDA to $95-$98M (up $5M), signaling improving operational momentum from distributor transitions and Medicare reimbursement restoration. Despite continued GAAP losses, the raised guidance and double-digit growth in Spine Fixation (+10% CC) and Limb Reconstruction (+11% CC) are key positives for the turnaround story.
Key Financial Metrics
Key Facts
- Q2 2026 reported net sales $210.9M, +3.8% reported / +4.7% pro forma constant currency YoY
- GAAP net loss $(15.8)M ($0.39/share) vs $(14.1)M ($0.36/share) in Q2 2025
- Non-GAAP adjusted EBITDA $20.1M (9.6% of pro forma sales) vs $20.6M (10.3%) prior year
- Full-year 2026 guidance raised: net sales $845M-$855M (from $838M-$848M), adj. EBITDA $95M-$98M (from $90M-$93M)
- Global Spine Fixation +10% constant currency; Global Limb Reconstruction +11% constant currency
- Cash used for arbitration and settlement payments to three former executives terminated in 2023
Financial Impact
Q2 revenue $210.9M, FY guidance raised by $7M to $845-855M; EBITDA guidance raised by $5M to $95-98M
Risk Factors
- Still GAAP unprofitable with negative free cash flow (-$47.1M YTD)
- Restructuring and integration risks from SeaSpine merger
- Ongoing litigation and investigation costs ($2.2M in Q2)
- Competitive pressure from larger players (Medtronic, Globus, Alphatec)
- Reliance on distributor transitions for U.S. spine growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-333817 |
| Document: ofix-20260805.htm | 0001193125-26-333817 |
| Document: ofix-ex99_2.htm | 0001193125-26-333817 |
| Document: 0001193125-26-333817-index-headers.html | 0001193125-26-333817 |
| Document: 0001193125-26-333817-index.html | 0001193125-26-333817 |
| Document: 0001193125-26-333817.txt | 0001193125-26-333817 |
| 8-K Data (Synthetic) | 0001193125-26-333817 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | Insider Buy | $9.18 $9.74 | ▲ +6.10% | ▲ +5.41% | $9.81 (+6.86%) |
Aug 20, 2026 9w ago | Insider Cluster | $10.01 $8.95 | ▼ −10.59% | ▼ −10.06% | $9.81 (−2.00%) |
Aug 5, 2026 11w ago | 8-K | $10.42 $9.38 | ▼ −9.98% | ▼ −9.38% | $9.81 (−5.85%) |
Jul 2, 2026 16w ago | 8-K | $9.94 $11.79 | ▲ +18.61% | ▲ +19.03% | $9.81 (−1.31%) |
May 21, 2026 22w ago | 8-K | $10.41 $8.90 | ▲ +14.55% | ▲ +14.89% | $9.81 (+5.76%) |
May 5, 2026 25w ago | 8-K | $12.44 $9.71 | ▼ −21.95% | ▼ −26.90% | $9.81 (−21.14%) |
Apr 29, 2026 25w ago | DEFA14A | $11.76 $9.27 | ▼ −21.17% | ▼ −26.40% | $9.81 (−16.58%) |
Apr 9, 2026 28w ago | 8-K | $12.42 $12.19 | ▼ −1.85% | ▼ −9.42% | $9.81 (−21.01%) |
Mar 10, 2026 32w ago | Insider Cluster | $12.27 $12.42 | ▲ +1.22% | ▲ +0.69% | $9.81 (−20.05%) |
Mar 5, 2026 33w ago | Insider Cluster | $12.57 $11.53 | ▲ +8.27% | ▲ +4.49% | $9.81 (+21.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers